Oculis Eyes Double DIAMOND After Initial Phase III Success In DME
Plans For Ex-US Partnerships
The Swiss firm’s lead candidate has hit the mark in the first stage of a pivotal diabetic macular edema program, edging closer to becoming the first eye drop treatment for a condition where unmet need remains despite the advent of anti-VEGFs.
You may also be interested in...
Regeneron Hopes Its High-Dose Aflibercept Will Ease Eylea Pressure
Eylea sales were below consensus for the second quarter in a row, but aflibercept 8mg approval in late June could offset the decline. Also, a late 2023 filing is planned for linvoseltamab in myeloma.
Roche’s Vabysmo Grabs Top Growth Spot As Sales Decline
The Swiss major’s Q1 earnings show significant growth for Vabysmo, which poses a threat to competitor anti-VEGF drugs from the likes of Novartis and Bayer, even as overall group sales decreased.
NASDAQ Listing Done, Oculis Eyes Phase III Readouts
Having taken the special purpose acquisition corporation route to list in the US, Switzerland's Oculis is waiting for some vital late-stage data, notably on OCS-01 for diabetic macular edema.